The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia

Yu Zhu; Liangqin Pan; Ming Hong; Weixing Liu; Chun Qiao; Jianyong Li; Sixuan Qian

doi:10.7555/JBR.30.20130172

🤖This page has been translated by AI and may contain inaccuracies. Please refer to the original content for clarification.

Home>Articles>The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia

DOI: 10.7555/JBR.30.20130172

The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia

Yu Zhu

Liangqin Pan

Ming Hong

Weixing Liu

Chun Qiao

Jianyong Li

Sixuan Qian

Keywords：chronic myeloid leukemiatyrosine kinase inhibitorsresistancecombined therapy

Publication Date：2016-01-01

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

The Journal of Biomedical Research

ISSN：1007-4368

Year, Vol.(Issue)：2016,30(6)